The Impact of the Lab4 Probiotic on the Wellbeing of Healthcare Workers: An Exploratory, Double-Blind, Randomised, Placebo-Controlled Study
- 1Cultech Ltd
Abstract
Healthcare workers face substantial occupational demands and exposure to respiratory infections during winter, but evidence that probiotics improve their health and wellbeing remains limited. This exploratory, double-blind, randomised, placebo-controlled trial assessed whether daily Lab4 supplementation affected upper respiratory tract infection (URTI) frequency and supported wellbeing in 104 healthcare workers. Daily diaries recorded symptoms defining URTI episodes, general-practitioner visits, illness-related work absence and antibiotic use. Wellbeing was assessed at baseline and weeks 8 and 16, and faecal microbiota were assessed using 16S rRNA gene sequencing. Participants receiving Lab4 reported better wellbeing than those receiving placebo. For probiotic versus placebo, the risk ratio (RR) for URTI occurrence was 0.60 (95% confidence interval [CI]: 0.30-1.20; p=0.1477), the incidence rate ratio (IRR) for episodes was 0.58 (95% CI: 0.27-1.23; p=0.1581), and the mean ratio for episode duration was 0.98 (95% CI: 0.72-1.32; p=0.8776). For general-practitioner visits, the RR for at least one visit was 0.48 (95% CI: 0.21-1.07; p=0.0737) and the IRR was 0.44 (95% CI: 0.18-1.06; p=0.0677). For illness-related work absence, the RR for at least one day absent was 0.75 (95% CI: 0.18-3.22; p=0.6991) and the IRR for absence days was 0.74 (95% CI: 0.16-3.32; p=0.6914). For antibiotic use, the RR for any use was 0.48 (95% CI: 0.20-1.18; p=0.1111) and the IRR for antibiotic-use days was 0.42 (95% CI: 0.16-1.12; p=0.0820). No significant between-group differences in gut microbiota were detected in the subset providing faecal samples. Illness-related estimates generally favoured Lab4, although between-group differences were not statistically significant. These exploratory findings support evaluation in a larger, prospectively powered trial.
Related
- Common elements-based nurturing care intervention to improve mother-infant responsive interaction and maternal psychological wellbeing in rural Pakistan: findings of a single-blinded individual randomised controlled trial.
- Effects of Probiotic Supplementation on Performance Retention During Detraining and Recovery After Simulated Return-to-Training Stress in College Volleyball Players: An Exploratory Randomized, Single-Blind, Placebo-Controlled Trial
- Protocol for the Nutrition OUtReach In Systems of Healthcare (NOURISH) trial: a phase II multicentre, parallel-group randomised controlled trial of medically tailored groceries to prevent malnutrition in transplant and cellular therapy patients
- Investigating the Effect of Oral Probiotic Capsules on Postpartum Sleep Quality in Primiparous Women: A triple-blind randomised controlled trial.
- A Short Evidence-Based, Belief-Focused Educational Video Improves Back Pain Beliefs but Not Lifting Behaviour in Healthy Office Workers: An Exploratory Randomised Controlled Trial.
BibTeX
@misc{dokic2026impact,
title = {{The Impact of the Lab4 Probiotic on the Wellbeing of Healthcare Workers: An Exploratory, Double-Blind, Randomised, Placebo-Controlled Study}},
author = {D. Dokic and A. A. Jack and N. Coates and D. A. John and I. Garaiova and J. A. K. McDonald and J. R. Marchesi and D. Wang and S. F. Plummer and D. R. Michael},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.29.26364268},
url = {https://www.medrxiv.org/content/10.64898/2026.09.29.26364268v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - The Impact of the Lab4 Probiotic on the Wellbeing of Healthcare Workers: An Exploratory, Double-Blind, Randomised, Placebo-Controlled Study
AU - D. Dokic
AU - A. A. Jack
AU - N. Coates
AU - D. A. John
AU - I. Garaiova
AU - J. A. K. McDonald
AU - J. R. Marchesi
AU - D. Wang
AU - S. F. Plummer
AU - D. R. Michael
PY - 2026
DA - 2026/09/29
PB - medRxiv
DO - 10.64898/2026.09.29.26364268
UR - https://www.medrxiv.org/content/10.64898/2026.09.29.26364268v1
AB - Healthcare workers face substantial occupational demands and exposure to respiratory infections during winter, but evidence that probiotics improve their health and wellbeing remains limited. This exploratory, double-blind, randomised, placebo-controlled trial assessed whether daily Lab4 supplementation affected upper respiratory tract infection (URTI) frequency and supported wellbeing in 104 healthcare workers. Daily diaries recorded symptoms defining URTI episodes, general-practitioner visits, illness-related work absence and antibiotic use. Wellbeing was assessed at baseline and weeks 8 and 16, and faecal microbiota were assessed using 16S rRNA gene sequencing. Participants receiving Lab4 reported better wellbeing than those receiving placebo. For probiotic versus placebo, the risk ratio (RR) for URTI occurrence was 0.60 (95% confidence interval [CI]: 0.30-1.20; p=0.1477), the incidence rate ratio (IRR) for episodes was 0.58 (95% CI: 0.27-1.23; p=0.1581), and the mean ratio for episode duration was 0.98 (95% CI: 0.72-1.32; p=0.8776). For general-practitioner visits, the RR for at least one visit was 0.48 (95% CI: 0.21-1.07; p=0.0737) and the IRR was 0.44 (95% CI: 0.18-1.06; p=0.0677). For illness-related work absence, the RR for at least one day absent was 0.75 (95% CI: 0.18-3.22; p=0.6991) and the IRR for absence days was 0.74 (95% CI: 0.16-3.32; p=0.6914). For antibiotic use, the RR for any use was 0.48 (95% CI: 0.20-1.18; p=0.1111) and the IRR for antibiotic-use days was 0.42 (95% CI: 0.16-1.12; p=0.0820). No significant between-group differences in gut microbiota were detected in the subset providing faecal samples. Illness-related estimates generally favoured Lab4, although between-group differences were not statistically significant. These exploratory findings support evaluation in a larger, prospectively powered trial.
ER -